CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
|Articles|November 1, 2017
- BioPharm International-11-01-2017
- Volume 30
- Issue 11
Dip-Molded Plastisol Y Connectors
Qosina's Y connectors are manufactured from plastisol and produced through a dip-molding process.
Advertisement
Qosina has added a variety of Y connectors manufactured from plastisol, also known as liquid polyvinyl chloride (PVC), a material used to make flexible components. According to the company, plastisol is Class VI approved and BPA and latex free. These connectors are produced through a dip-molding process rather than traditional injection molding.
The company offers standard and universal plastisol Y connectors. The universal style can be cut to accommodate 3/32, 1/8, 3/16, and 1/4 in. OD tubes. There are 15 different Y connector configurations, sample assortment kits, and custom design services available to meet requirements for a range of projects.
Articles in this issue
almost 9 years ago
Connector Integrity in Single-Use Biomanufacturing Systemsalmost 9 years ago
FDA Overhauls Inspection Process and Field Operationsalmost 9 years ago
ADC Development Robust Despite Lackluster Performancealmost 9 years ago
Change Control for Standard Operating Proceduresalmost 9 years ago
CDMO Acquisitions Build Strategic Supplier Basealmost 9 years ago
Pump Head for Shear-Sensitive Pumpingalmost 9 years ago
Analytical Data System Updatealmost 9 years ago
Temperature-Controlled Shipping Solutionalmost 9 years ago
Evaluating Surface Cleanliness Using a Risk-Based Approachalmost 9 years ago
Awards Recognize Bio/Pharma Industry ContributionsAdvertisement
Related to this article
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Former FDA oncology reviewer Paz Vellanki, MD, PhD, of Precision for Medicine, discusses how CDER's ARC program supports novel end points such as ctDNA for rare diseases and why sponsors should engage FDA early.
Following an FDA meeting, Wave Life Sciences plans a single 2-year registrational trial of WVE-006, its GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, with a 1-year interim analysis that could support accelerated approval based on biomarkers.
Advertisement
Advertisement